Global Bladder Cancer Therapeutics Market to Grow at a CAGR of 4.7% by 2021 - Key Vendors are Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche & Pfizer - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Bladder Cancer Therapeutics Market 2017-2021" report to their offering.

The global bladder cancer therapeutics market to grow at a CAGR of 4.77% during the period 2017-2021.

The report, Global Bladder Cancer Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is advent of novel pipeline. The global bladder cancer therapeutics market is expected to grow due to the presence of novel therapies in the early stages of the pipeline. For instance, the adoptive cell therapy utilizes the immunotherapy approach for the treatment of bladder cancer.

According to the report, one driver in the market is growing prevalence rate leads to higher prescription value. Bladder cancer is the ninth-most type of cancer diagnosed worldwide, with the highest incidence rates demonstrated by males in Southern and Western Europe, North America, and in certain countries in Northern Africa or Western Asia. Bladder cancer ranked among 15 most common causes of deaths worldwide.

Key vendors

  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hoffman-La Roche
  • Pfizer

Other prominent vendors

  • Accord Healthcare
  • AstraZeneca
  • Bedford Lab
  • Merck
  • Sanofi

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Key clinical trials

PART 06: Market landscape

PART 07: Market segmentation by therapy

PART 08: Geographical segmentation

PART 09: Decision framework

PART 10: Drivers and challenges

PART 11: Market trends

PART 12: Vendor landscape

PART 13: Key vendor analysis

PART 14: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/3xp5xx/global_bladder

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Bladder Cancer Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Bladder Cancer Drugs